X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will be used to initiate and complete the first-in-human Phase 1 clinical trial and reach Phase 2 readiness for Resalis’ lead program, RES-010, a non-coding RNA-based compound, in obesity.
Lead Product(s): RES-010
Therapeutic Area: Nutrition and Weight Loss Product Name: RES-010
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sunstone Life Science Ventures
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 04, 2024
Details:
The funding will support the finalization of IND-enabling studies for the company’s lead program, RES-010, which Resalis will initially develop as a novel treatment for obesity and nonalcoholic fatty liver disease (NAFLD).
Lead Product(s): Non-Coding RNA-Based Therapy
Therapeutic Area: Nutrition and Weight Loss Product Name: RES-010
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Claris Ventures
Deal Size: $10.6 million Upfront Cash: Undisclosed
Deal Type: Financing February 22, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
